Navigation Links
American Oriental Bioengineering Comments on Earthquake
Date:5/15/2008

NEW YORK, May 15 /PRNewswire-FirstCall/ -- American Oriental Bioengineering, Inc. (NYSE: AOB), a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter ("OTC") products in China, today released the following statement regarding the earthquake in China:

"Our thoughts are with the many victims of China's earthquake and we are thankful to report that none of our staff was hurt in the tragic events. Our manufacturing, production and overall operations were not impacted by the earthquake and we do not anticipate any damage-related impact to our sales in the second quarter," stated Mr. Tony Liu, Chairman and Chief Executive Officer of American Oriental Bioengineering.

About American Oriental Bioengineering Inc.

American Oriental Bioengineering Inc. is a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter products in China. For more information, visit http://www.bioaobo.com.

Statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements. The economic, competitive, governmental, technological and other factors identified in the Company's filings with the Securities and Exchange Commission, including the Form 10-K for the year ended December 31, 2007, may cause actual results or events to differ materially from those described in the forward looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.


'/>"/>
SOURCE American Oriental Bioengineering, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Moffitt Cancer Center Joins National Campaign To Implore Americans To Donate $1 To Accelerate Cancer Research
2. American Oriental Bioengineering Reports First Quarter 2008 Financial Results
3. LifeQuest World Launches Immune System Boosting Supplement to the North American Market
4. American Psychiatric Foundation Announces Recipients of 2008 Awards for Advancing Minority Mental Health
5. YM BIOSCIENCES ANNOUNCES PRESENTATIONS FOR AEROLEF(TM) AT AMERICAN PAIN SOCIETY ANNUAL MEETING
6. Aflac and the American Association for Cancer Research Unite to Issue Inaugural Aflac Career Development Award for Childhood Cancer Research
7. American Oriental Bioengineering to Report First Quarter 2008 Financial Results
8. FASgen, Inc. Presents Ovarian Cancer Efficacy and Toxicology Data to the American Association for Cancer Research
9. Telik Presents Preclinical Data at 99th Annual Meeting of the American Association for Cancer Research
10. SPO Medical Retains American Capital Ventures for Investor Relations Services
11. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the Annual Meeting of the American Association for Cancer Research (AACR); Scientific Advisory Board Chairman Tyler Jacks Named President-elect
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... ... ... Academy of Model Aeronautics (AMA), the nation’s leading voice ... systems (UAS), are launching a joint program to promote safe and responsible drone ... efforts. , AMA and DJI will collaborate on other potential opportunities to mutually ...
(Date:2/16/2017)... ... February 16, 2017 , ... Avomeen & MichBio will be hosting a ... held at Avomeen Analytical Services (4840 Venture Dr., Ann Arbor, Michigan 48108). BioMixers ... an opportunity to interact with peers, make new connections and talk bio biz. , ...
(Date:2/16/2017)... , Feb. 16, 2017  MDNA Life ... the development of liquid biopsy tests based on ... into an exclusive license agreement with its first ... proprietary liquid biopsy test for prostate cancer, the ... Korea . This is the first overseas ...
(Date:2/16/2017)... 16, 2017   Capricor Therapeutics, Inc. ... company developing first-in-class biological therapies for cardiac and ... elected to terminate its license agreement with the ... including Cenderitide. "Our decision to return ... prioritize our efforts to advance our core cell ...
Breaking Biology Technology:
(Date:1/21/2017)... Research and Markets has announced the addition of the ... offering. ... global voice recognition biometrics market to grow at a CAGR of ... the present scenario and the growth prospects of the global voice ... report considers the revenue generated from the sales of voice recognition ...
(Date:1/18/2017)... Md. , Jan. 18, 2017  In vitro ... respect to mergers and acquisitions (M&A), and Kalorama Information ... for such acquisitions have been shifting. Generally, uncertainty in ... and the U.S. has changed the acquisitions landscape. ... has resulted in companies buying partners outside of their ...
(Date:1/12/2017)... , Jan. 12, 2017  Trovagene, Inc. (NASDAQ: ... DNA (ctDNA) technologies, today announced that it has signed ... and the Middle East ...  This milestone marks the first wave of international distribution ... urine and blood samples. The initial partners ...
Breaking Biology News(10 mins):